Multiple sclerosis relapse: FDA reporting patterns
68,223 FDA FAERS reports mention Multiple sclerosis relapse. 48,916 reports have a serious outcome flag.
Medicines named as suspect
- Natalizumab: 16,514 reports
- Interferon Beta-1a: 13,564 reports
- Dimethyl Fumarate: 7,724 reports
- Fingolimod: 7,705 reports
- Teriflunomide: 4,972 reports
- Glatiramer: 4,651 reports
- Dalfampridine: 3,803 reports
- Ocrelizumab: 2,532 reports
- Interferon Beta-1b: 2,254 reports
- Ofatumumab: 1,646 reports
- Peginterferon Beta-1a: 953 reports
- Diroximel: 950 reports
FAERS reports describe events reported after a medicine was taken. They do not prove that the medicine caused an event, measure how often a side effect occurs, or estimate personal risk.
Source: FDA FAERS via openFDA. FAERS data through 2026-06-30. Sources, methods, and limitations.